I

Instil Bio Inc
NASDAQ:TIL

Watchlist Manager
Instil Bio Inc
NASDAQ:TIL
Watchlist
Price: 11.12 USD 2.58% Market Closed
Market Cap: 75.4m USD

Instil Bio Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Instil Bio Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
I
Instil Bio Inc
NASDAQ:TIL
Non-Reccuring Items
-$17m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$10.7B
CAGR 3-Years
-72%
CAGR 5-Years
-60%
CAGR 10-Years
-27%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$843m
CAGR 3-Years
38%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
-$3.2B
CAGR 3-Years
-87%
CAGR 5-Years
N/A
CAGR 10-Years
-35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$543m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
-60%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$245.5m
CAGR 3-Years
26%
CAGR 5-Years
-10%
CAGR 10-Years
-20%
No Stocks Found

Instil Bio Inc
Glance View

Market Cap
75.4m USD
Industry
Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.

TIL Intrinsic Value
4.3 USD
Overvaluation 61%
Intrinsic Value
Price
I

See Also

What is Instil Bio Inc's Non-Reccuring Items?
Non-Reccuring Items
-17m USD

Based on the financial report for Dec 31, 2024, Instil Bio Inc's Non-Reccuring Items amounts to -17m USD.

What is Instil Bio Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
76%

Over the last year, the Non-Reccuring Items growth was 76%.

Back to Top